GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Total Liabilities

Boiron (FRA:BON) Total Liabilities : €198.7 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Boiron Total Liabilities?

Boiron's Total Liabilities for the quarter that ended in Dec. 2023 was €198.7 Mil.

Boiron's quarterly Total Liabilities declined from Dec. 2022 (€232.15 Mil) to Jun. 2023 (€202.75 Mil) and declined from Jun. 2023 (€202.75 Mil) to Dec. 2023 (€198.70 Mil).

Boiron's annual Total Liabilities declined from Dec. 2021 (€238.93 Mil) to Dec. 2022 (€232.15 Mil) and declined from Dec. 2022 (€232.15 Mil) to Dec. 2023 (€198.70 Mil).


Boiron Total Liabilities Historical Data

The historical data trend for Boiron's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Total Liabilities Chart

Boiron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 258.82 272.65 238.93 232.15 198.70

Boiron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 238.93 237.91 232.15 202.75 198.70

Boiron Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Boiron's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=126.329+(6.645+5.245
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+60.482)
=198.7

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=590.201-391.5
=198.7

Boiron's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=126.329+(6.645+5.245
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+60.482)
=198.7

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=590.201-391.5
=198.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boiron Total Liabilities Related Terms

Thank you for viewing the detailed overview of Boiron's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Boiron (FRA:BON) Business Description

Traded in Other Exchanges
Address
2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.